Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement regarding the Notice of 47th Annual General Meeting and E-Voting Information.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026, along with the Annual Report for the FY 2025-26.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'providing a web-link of the Annual Report 2025-26 to members'. The company has issued letters to shareholders whose e-mail addresses are not registered with the Company/Depository Participants, providing the web-link along with the path to access the Annual Report 2025-26 including Notice of AGM of the Company on the Company's website.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022'.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication regarding the 47th Annual General Meeting (AGM) of the company to be held on September 18, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM).

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 earnings, reporting a 9% growth in sales and 21% growth in operating EBITDA and net profits. The company has also acquired a controlling stake in Aequitas Healthcare for Rs.25 crores and completed a Rs.40 crores share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 earnings, with a 9% growth in sales and 21% growth in operating EBITDA and net profits. The company has also acquired a controlling stake in Aequitas Healthcare for Rs.25 crores and completed a Rs.40 crores share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has made available the audio recording of its Q1 FY27 Earnings Conference Call on its website, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding Extract of Unaudited Financial Results for the quarter ended June 30, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about change in Management, designating Mr. Balmukund Keshav as Deputy General Manager (Information Technology) and Mr. Sanjay Singhal as General Manager (CQA & Regulatory Affairs) effective July 29, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about the grant of 1,20,000 employee stock options under Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue up 9% YoY, PAT up 22% YoY, and cash reserves at ₹1,700 Mn. The company has also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 results, with revenue up 9% YoY, PAT up 22% YoY, and cash reserves at ₹1,700 Mn. The company has also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced the record date for the purpose of dividend as 04-Sep-2026, with a recommended dividend of Rs. 4/- (200%) per equity share for the financial year ended March 31, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on July 29, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has scheduled a conference call with analysts and investors on July 30, 2026, to discuss its Q1 FY27 financial results.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the allotment of 94,000 equity shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022) to eligible employees.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals has completed the acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited, as per its proposed acquisition of 85% stake.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the completion of acquisition of 69.77% stake in Aequitas Healthcare Private Limited, making Aequitas a subsidiary of Jagsonpal.